 |
|
Every patient is unique: Individualized therapies for non-Hodgkin's lymphoma
June 17, 2008PET's ability to identify patients who will respond to treatments could advance personalized medicine
NEW ORLEANS, La.-Positron emission tomography (PET) could be an important tool for identifying non-Hodgkin's lymphoma patients who are likely to respond well to treatment with 90 ibritumomab tiuxetan (IT)-the first radioimmunotherapy treatment approved for use by the U.S. Food and Drug Administration, said researchers at SNM's 55th Annual Meeting. PET imaging allows practitioners to identify patients who could be treated, predict how they would respond and identify relapses early in patients who have follicular lymphoma, a common type of slow-growing lymphoma.
"This study illustrates how PET could be used to advance the goal of personalized medicine-identifying and targeting the right treatment for each individual," said Stefano Fanti, professor of nuclear medicine at the Policlinico S. Orsola-Università di Bologna in Bologna, Italy, and a researcher of this study. "The functional data provided by PET are essential for determining stages of cancer, detecting disease relapses and evaluating how patients respond to particular therapies. Our study clearly indicates that the next step-using PET for predicting how patients will respond to treatment-can be achieved."
In the United States, about 65,000 new cases of non-Hodgkin's lymphoma are diagnosed every year. The number of new cases is on the rise, especially among older people and people whose immune systems are not functioning normally. Those at risk include people who have had organ transplants and those with human immunodeficiency virus (HIV).
Non-Hodgkin's lymphomas are a diverse group of cancers that develop in B or T lymphocytes, which are white blood cells that normally defend the body against bacteria and other pathogens. This group of cancers is actually the cause of more than 20 diseases, which have distinct appearances under the microscope and different clinical courses. Most non-Hodgkin's lymphomas are from B cells.
IT is a monoclonal antibody used in conjunction with radioactive medications to treat non-Hodgkin's lymphoma patients who have relapsed after treatment or for those with slow-growing forms of the disease such as follicular lymphoma. While there have been studies to investigate the usefulness of PET in patients with lymphoma and research into the effectiveness of radioimmunotherapy, no data were available regarding the role of PET in determining whether patients would be good candidates for IT.
In their study, Fanti and his team examined 38 non-Hodgkin's lymphoma patients who were treated with IT after a relapse. PET scans were taken before IT treatment and then three months after treatment began. All patients had a final assessment at six months using clinical data.
Results indicated that the first set of PET scans detected the relapse and extent of the disease in all of the patients. At the six-month follow up, 89 percent of the patients were either in complete or partial remission after the IT treatment. Comparison of PET data on the extent of patients' disease at relapse and their response after three months indicated a higher rate of response to the treatment in patients whose cancer was limited. In all of the cases, the findings of the PET scans at three months were consistent with the clinical findings at six months.
Society of Nuclear Medicine
In the United States, about 65,000 new cases of non-Hodgkin's lymphoma are diagnosed every year. The number of new cases is on the rise, especially among older people and people whose immune systems are not functioning normally. Those at risk include people who have had organ transplants and those with human immunodeficiency virus (HIV).
Non-Hodgkin's lymphomas are a diverse group of cancers that develop in B or T lymphocytes, which are white blood cells that normally defend the body against bacteria and other pathogens. This group of cancers is actually the cause of more than 20 diseases, which have distinct appearances under the microscope and different clinical courses. Most non-Hodgkin's lymphomas are from B cells.
IT is a monoclonal antibody used in conjunction with radioactive medications to treat non-Hodgkin's lymphoma patients who have relapsed after treatment or for those with slow-growing forms of the disease such as follicular lymphoma. While there have been studies to investigate the usefulness of PET in patients with lymphoma and research into the effectiveness of radioimmunotherapy, no data were available regarding the role of PET in determining whether patients would be good candidates for IT.
In their study, Fanti and his team examined 38 non-Hodgkin's lymphoma patients who were treated with IT after a relapse. PET scans were taken before IT treatment and then three months after treatment began. All patients had a final assessment at six months using clinical data.
Results indicated that the first set of PET scans detected the relapse and extent of the disease in all of the patients. At the six-month follow up, 89 percent of the patients were either in complete or partial remission after the IT treatment. Comparison of PET data on the extent of patients' disease at relapse and their response after three months indicated a higher rate of response to the treatment in patients whose cancer was limited. In all of the cases, the findings of the PET scans at three months were consistent with the clinical findings at six months.
Society of Nuclear Medicine
Lymphoma News and Current Lymphoma Events RSSResearchers discover how rheumatoid arthritis causes bone loss
Researchers have discovered key details of how rheumatoid arthritis (RA) destroys bone, according to a study published in the Aug. 22 edition of the Journal of Biological Chemistry.
Duke chemists synthesize promising anti-cancer product
Duke University chemists have patented an efficient technique for synthesizing a marine algae extract in sufficient quantities to now test its ability to inhibit the growth of cancerous cells while leaving normal cells unaffected.
Children's national co-leads nationwide study of landmark sickle cell treatment
Children's National Medical Center immunologist and blood and marrow transplant physician Naynesh Kamani, MD, will serve as the study co-chair for a new national clinical trial of unrelated donor marrow and umbilical cord blood transplants for severe sickle cell disease.
Rheb's role in cancer
Two independent papers in the August 15th issue of G&D identify the Rheb GTPase as a novel oncogene and a promising new chemotherapeutic target.
Researchers find cancer-inhibiting compound under the sea
University of Florida College of Pharmacy researchers have discovered a marine compound off the coast of Key Largo that inhibits cancer cell growth in laboratory tests, a finding they hope will fuel the development of new drugs to better battle the disease.
Targeted drug therapy found effective in patients with common form of immune-mediated kidney disease
The drug rituximab causes considerable kidney injury healing in patients with membranous nephropathy, a common form of kidney disease, according to a study appearing in the November 2008 issue of the Clinical Journal of the American Society Nephrology (CJASN). The results suggest that this condition, previously destined to progress to kidney failure in 30-40 percent of cases, can actually be healed in some patients.
Exposure to Agent Orange linked to prostate cancer in Vietnam veterans
UC Davis Cancer Center physicians today released results of research showing that Vietnam War veterans exposed to Agent Orange have greatly increased risks of prostate cancer and even greater risks of getting the most aggressive form of the disease as compared to those who were not exposed.
New Guidelines for Treating Rheumatoid Arthritis
Proven combinations of medicines and the introduction of new anti-arthritis drugs have significantly improved the treatment of rheumatoid arthritis (RA), according to guidelines issued by the American College of Rheumatology and co-authored by physicians at the University of Alabama at Birmingham (UAB).
Plants make vaccine for treating type of cancer in Stanford study
Plants could act as safe, speedy factories for growing antibodies for personalized treatments against a common form of cancer, according to new findings from the Stanford University School of Medicine. The findings came in the first human tests of an injectable vaccine grown in genetically engineered plants.
CSHL scientists correlate enzyme expression levels with chemotherapy drug response
Why do cancer patients develop resistance to chemotherapy drugs, sometimes abruptly, after a period in which the drugs seem to be working well to reduce tumors or hold them in check? Although largely a mystery to scientists, the result when this occurs is all too familiar: patients relapse and in many cases die when their cancers become resistant.
More Lymphoma News Articles
 | Living with Lymphoma: A Patient's Guide by Elizabeth M. Adler "Adler's professional background and experience as a lymphoma survivor make her the perfect person to write this book. The author's explanations are a gentle guide and a thorough introduction to the basics that give us the confidence to handle decisions relating to treatments and other aspects of lymphoma." -- Anne Atkinson, non-Hodgkin lymphoma and Hodgkin disease survivor and coordinator of the... |
 | Ioachim's Lymph Node Pathology Now in its Fourth Edition, this comprehensive, practical, and thoroughly illustrated reference offers valuable guidance in the diagnostic interpretation of lymph node biopsies. It provides encyclopedic coverage of all the various nonmalignant lesions, lymphomas, other neoplasms, and metastatic tumors in lymph nodes. The discussion of each pathologic entity includes definition, clinical syndrome,... |
 | 100 Questions & Answers About Lymphoma by Peter Holman, Jodi Garrett, William D. Jansen This book deals with lymphoma from a doctor's and a caregiver's... |
 | Salivary Gland Cytopathology (Essentials in Cytopathology) by William C. Faquin, Celeste N. Powers Salivary gland cytopathology is one of the most challenging areas of diagnostic cytology. Salivary Gland Cytopathology will use a simplified algorithmic approach based upon differential diagnostic groups to cover practical aspects of diagnosing common as well as challenging salivary gland lesions. This volume published in the “Essentials in Cytopathology” book series will fulfill... |
 | Surviving Has Made Me Crazy by Mark Nepo Poet and philosopher Mark Nepo was diagnosed with a rare form of lymphoma in 1987. His journey back to health awakened a new life. In his latest book, Nepo explores how sacred and useful everything is. As such, this book is for everyone, not just for those facing illness or pursuing poetry. The poems affirm that surviving has more to do with our authenticity than our longevity. The sixty-eight... |
 | Non-Hodgkin's Lymphomas: Making Sense of Diagnosis, Treatment and Options by Lorraine Johnston Prior to publication of this resource guide, no book on the market targeted the non-Hodgkin's lymphoma survivor's need for understandable information. While there are medical texts on the non-Hodgkin's lymphomas as well as inspirational first-person accounts from survivors of related cancers such as leukemia, between these two sources of information existed a considerable information gap. In... |
 | Patient Number One: A True Story of How One CEO Took on Cancer and Big Business in the Fight of His Life by Rick Murdock, David Fisher Cancer is a terrorist, driving us mad with feelings of hopelessness and despair. One man, faced with lymphatic cancer and a poor prognosis, had the unique opportunity to influence not just the course of his treatment, but the research guiding that treatment. Patient Number One tells the story of Rick Murdock, former CEO of CellPro, a Seattle biotech company specializing in cell separation--as it... |
 | An Illustrated Guide to Skin Lymphoma by Lorenzo Cerroni, Kevin Gatter, Helmut Kerl Skin lymphomas are relatively rare. They may arise in the skin itself and as a by-product of HIV infection, or may arise elsewhere as a result of Hodgkin's disease, B cell lymphomas or leukaemia. Whatever the cause, they can easily be overlooked as psoriasis or dermatitis. Diagnosis of skin lymphoma is difficult and making the wrong diagnosis can prove fatal. Consequently, those in training in... |
 | 100 Questions & Answers About Lymphoma by Peter Holman, MD - Jodi Garrett, RN - William Jansen by MD - Jodi Garrett, RN - William Jansen Peter Holman JC#1 - Brand New/Selead - What is lymphoma? What causes lymphoma? What are the options available for the treatment of lymphoma? What are the common reactions to being diagnosed with lymphoma? Thank You For... |
 | Bald in the Land of Big Hair: A True Story by Joni Rodgers Bald in the Land of Big Hair is the hilarious-and often heartbreaking-tale of Joni Rodgers's journey through the badlands of cancer told with humor, occasional anger, and unflinching honesty. More than just a cancer book, this is a deeply affecting memoir of one woman's struggle to come to terms with everything that life throws her way.Ultimately, this is a moving celebration of the true meaning... |
| © 2008 BrightSurf.com |